Queensland Awards $7.7 Million to BioOra for Onshore CAR T-Cell Manufacturing Facility
核心洞察
The Crisafulli Government awarded NZ$7.7 million to BioOra Pty Ltd (搜索) through the $180.6 million Sovereign Industry Development Fund to establish a CAR T-cell manufacturing suite in Brisbane.
The automated clinical and commercial-scale facility will be located at ENTRI within the Boggo Road Innovation Junction, with operations expected by 2028.
The project will create 72 highly skilled jobs and reduce Australia's reliance on overseas manufacturing of advanced cell therapies.
The Crisafulli Government has awarded $7.7 million to New Zealand-based BioOra Pty Ltd (搜索) to establish an automated clinical and commercial-scale CAR T-cell manufacturing suite in Brisbane, marking a significant step toward onshoring advanced cell therapy production in Australia.
The funding, drawn from the government's flagship $180.6 million Sovereign Industry Development Fund (SIDF), will support the fit-out of BioOra's manufacturing facility at ENTRI, located within the Boggo Road Innovation Junction (BRIJ) in Woolloongabba. The facility is expected to be operational by 2028.
Strategic Investment in Sovereign Capability
The SIDF forms part of the Crisafulli Government's broader plan to reverse what it describes as a decade of economic decline in Queensland's advanced manufacturing sectors. The fund targets high-value industries including biomedical manufacturing, defence, and biofuels, with the explicit goal of securing sovereign capability, attracting private investment, and creating highly skilled jobs.
Deputy Premier and Minister for State Development, Infrastructure and Planning Jarrod Bleijie framed the investment as a corrective to previous government inaction. "We inherited an economy that had suffered through a decade of thought bubbles and glossy brochures, with no real action, too many opportunities lost and too little focus on building Queensland's sovereign capability," Bleijie said.
"While Labor talked about the industries of the future, the Crisafulli Government is taking action to support them and this investment in BioOra will help establish Queensland as a leader in advanced biomedical manufacturing, supporting the development of life-saving therapies while creating highly skilled jobs and attracting further private sector investment."
CAR T-Cell Therapy: Personalised Cancer (搜索) Treatment
CAR T-cell therapies represent a form of personalised cancer (搜索) treatment in which a patient's own immune cells are harvested, genetically modified to recognise and destroy cancer cells, and then reinfused. By onshoring production, the project aims to reduce Australia's reliance on overseas manufacturing, improve patient access to these cutting-edge treatments, and strengthen Queensland's competitive position in a rapidly expanding global sector.
The investment is projected to create 72 high-value, highly skilled jobs and will advance BioOra's partnership with the Translational Research Institute (搜索) (TRI).
Accelerated Timeline and Industry Impact
BioOra CEO John Robson emphasised the catalytic effect of the government funding on the company's expansion strategy. "The support from SIDF accelerated our expansion plans into Australia by 18 months and will result in a significantly quicker delivery of sovereign capability of CAR-T cell manufacturing within the state," Robson said.
Robson further highlighted the importance of the TRI partnership: "The partnership that we are developing with TRI, and the potential of the infrastructure at ENTRI, will be pivotal in the successful transfer of our manufacturing expertise in cell and gene therapies to Australia, and in the resultant public availability of Australian made therapies."
Deputy Premier Bleijie underscored the long-term vision behind the investment, stating, "This investment will ensure that Queensland is not simply consuming innovation developed elsewhere, but becoming a place where breakthrough technologies are researched, manufactured and delivered to the world."